Dividend
-
-
-
-
-
-
-
Fortress Biotech unit to sell rare disease voucher for $205 million
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
-
-
-
-
-
-
-
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
-
-
-
-
-
-
-
Fortress Biotech (FBIO) Prices 3.94M Sharee Offering at $1.65/sh
-
-
-
-
-
-
-
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
-
444,849 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

